Background: Gastric pH changes by proton-pump-inhibitors (PPIs) were found to affect progression-free survival (PFS) in metastatic breast cancer (mBC) patients treated with palbociclib. The current study was aimed at investigating whether the same effect could occur in patients treated with ribociclib. Patients and methods: Patients with hormone-positive/HER-2-negative mBC candidates for first-line treatment with ribociclib were enrolled in this retrospective-cohort study. Patients were classified as "no concomitant PPIs" or "concomitant PPIs"; PPI administration covered the entire or not less than 2/3 of treatment with ribociclib. All clinical interventions were made according to clinical practice. Results: A total of 128 patients were consecutively enrolled in the study; 78 belonged to the "no concomitant PPIs" group and 50 to the "concomitant PPIs" group. One hundred and six patients were endocrine-sensitive and received ribociclib and letrozole, while 22 were endocrine-resistant and were treated with ribociclib and ful-vestrant. The most prescribed PPI was lansoprazole. According to PFS, patients taking PPIs had a PFS almost superimposable to those assuming ribociclib and endocrine therapy alone (35.3 vs. 49.2 months, p = 0.594). No difference in PFS was observed in estrogen-sensitive or estrogen-resistant mBC in the presence or absence of concomitant PPI treatment (p = 0.852). No correlation with adverse events was found including grade>2 he-matological toxicities. Conclusions: The present study supports the hypothesis that the concomitant use of PPIs does not compromise the efficacy of ribociclib in a real-life setting.

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib / Del Re, M.; Crucitta, S.; Omarini, C.; Bargagna, I.; Mongillo, M.; Palleschi, M.; Stucci, S.; Meattini, I.; D'Onofrio, R.; Lorenzini, G.; Biondani, P.; De Giorgi, U.; Porta, C.; Livi, L.; Natalizio, S.; Fontana, A.; Giontella, E.; Angelini, L.; Fogli, S.; Danesi, R.. - In: BREAST. - ISSN 1532-3080. - 66:(2022), pp. 157-161. [10.1016/j.breast.2022.10.005]

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib

Omarini C.;D'Onofrio R.;Natalizio S.;
2022

Abstract

Background: Gastric pH changes by proton-pump-inhibitors (PPIs) were found to affect progression-free survival (PFS) in metastatic breast cancer (mBC) patients treated with palbociclib. The current study was aimed at investigating whether the same effect could occur in patients treated with ribociclib. Patients and methods: Patients with hormone-positive/HER-2-negative mBC candidates for first-line treatment with ribociclib were enrolled in this retrospective-cohort study. Patients were classified as "no concomitant PPIs" or "concomitant PPIs"; PPI administration covered the entire or not less than 2/3 of treatment with ribociclib. All clinical interventions were made according to clinical practice. Results: A total of 128 patients were consecutively enrolled in the study; 78 belonged to the "no concomitant PPIs" group and 50 to the "concomitant PPIs" group. One hundred and six patients were endocrine-sensitive and received ribociclib and letrozole, while 22 were endocrine-resistant and were treated with ribociclib and ful-vestrant. The most prescribed PPI was lansoprazole. According to PFS, patients taking PPIs had a PFS almost superimposable to those assuming ribociclib and endocrine therapy alone (35.3 vs. 49.2 months, p = 0.594). No difference in PFS was observed in estrogen-sensitive or estrogen-resistant mBC in the presence or absence of concomitant PPI treatment (p = 0.852). No correlation with adverse events was found including grade>2 he-matological toxicities. Conclusions: The present study supports the hypothesis that the concomitant use of PPIs does not compromise the efficacy of ribociclib in a real-life setting.
2022
66
157
161
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib / Del Re, M.; Crucitta, S.; Omarini, C.; Bargagna, I.; Mongillo, M.; Palleschi, M.; Stucci, S.; Meattini, I.; D'Onofrio, R.; Lorenzini, G.; Biondani, P.; De Giorgi, U.; Porta, C.; Livi, L.; Natalizio, S.; Fontana, A.; Giontella, E.; Angelini, L.; Fogli, S.; Danesi, R.. - In: BREAST. - ISSN 1532-3080. - 66:(2022), pp. 157-161. [10.1016/j.breast.2022.10.005]
Del Re, M.; Crucitta, S.; Omarini, C.; Bargagna, I.; Mongillo, M.; Palleschi, M.; Stucci, S.; Meattini, I.; D'Onofrio, R.; Lorenzini, G.; Biondani, P.; De Giorgi, U.; Porta, C.; Livi, L.; Natalizio, S.; Fontana, A.; Giontella, E.; Angelini, L.; Fogli, S.; Danesi, R.
File in questo prodotto:
File Dimensione Formato  
PPI CDK.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 582.63 kB
Formato Adobe PDF
582.63 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1305347
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact